Celebrity Inventors
Mark Twain (Samuel L. Clemens) received Patent No. 121,992 for "An Improvement in Adjustable and Detachable Straps for Garments." He later received two more patents: one for a self-pasting scrapbook and one for a game to help players remember important historical dates.
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
US Patent 6207674 - Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US Patent Issued on March 27, 2001
Estimated Patent Expiration Date:
December 22, 2019Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Estimated Patent Expiration Date:
December 22, 2019Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.AbstractPatients can be helped to break free of addictive or habit-forming narcotics and anti-depressants, by treatment using two drugs. One drug is dextromethorphan (DM), which has been used for decades as an anti-tussive (cough-suppressing) drug in cough syrups. The other drug is an oxidase inhibitor which suppresses activity of a liver enzyme called cytochrome P450-2D6 (also called debrisoquin hydroxylase, sparteine monooxygenase, cytochrome P450-DB, and CYP2D6). In most patients, this oxidase enzyme rapidly degrades DM and converts it into a metabolite called dextrorphan. An oxidase inhibitor (such as quinidine) which suppresses cytochrome P450-2D6 activity increases the half-life and concentration of DM in the circulating blood. When this combined treatment was administered orally to patients who had become dependent on morphine and anti-depressant drugs because of chronic intractable pain, it initially helped the patients reduce their dosages of morphine and other drugs, including anti-depressants. When additional testing was done, the combined treatment allowed patients to entirely terminate all use of morphine and anti-depressants, with minimal withdrawal or other adverse effects. Importantly, these same patients received no substantial benefit from taking dm by itself, without an oxidase inhibitor. Accordingly, the combination of dextromethorphan plus an anti-oxidase drug can allow at least some patients to break entirely free of narcotics and/or anti-depressants, even after years of use for chronic pain and other medical problems, even when they are not substantially helped by dextromethorphan alone.Other References
| InventorApplicationNo. 471060 filed on 12/22/1999US Classes:514/289, Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)514/305, Quinuclidines (including unsaturation)514/491, With an additional active ingredient514/649, Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain514/651, Ether oxygen is part of the chain514/652, Alkanol group only between the amino nitrogen and an ether oxygen which is bonded directly to the aryl ring or aryl ring system (i.e., aryloxy alkanol amines)514/654The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents onlyField of Search514/289, Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)514/305, Quinuclidines (including unsaturation)514/491, With an additional active ingredient514/649, Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain514/651, Ether oxygen is part of the chain514/652, Alkanol group only between the amino nitrogen and an ether oxygen which is bonded directly to the aryl ring or aryl ring system (i.e., aryloxy alkanol amines)514/654The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents onlyExaminersPrimary: Krass, FrederickAssistant: Jagoe, Donna Attorney, Agent or FirmUS Patent References4316888, Method and composition of reducing painIssued on: 02/23/1982 Inventor: Nelson5166207, Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders Issued on: 11/24/1992 Inventor: Smith5206248, Method for reducing emotional lability Issued on: 04/27/1993 Inventor: Smith5321012, Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance Issued on: 06/14/1994 Inventor: Mayer, et al.5350756, Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan Issued on: 09/27/1994 Inventor: Smith5352683, Method for the treatment of chronic pain Issued on: 10/04/1994 Inventor: Mayer, et al.5366980, Use of dextromethorphan and an oxidase inhibitor to treat dermatitis Issued on: 11/22/1994 Inventor: Smith5502058, Method for the treatment of pain Issued on: 03/26/1996 Inventor: Mayer, et al.5556838, Inhibiting the development of tolerance to and/or dependence on an addictive substance Issued on: 09/17/1996 Inventor: Mayer, et al.5863927Dextromethorphan and an oxidase inhibitor for treating intractable conditions Issued on: 01/26/1999 Inventor: Smith, et al. International ClassesA61K 31//44.31/27 31/135 |
